Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Feb
04
More than Medicine: UCB's Holistic Approach to Supporting MG Patients
Dec
08
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
Dec
04
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
Dec
03
Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program
Nov
14
When Every Second Matters
Nov
04
Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)
Nov
03
U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Oct
31
Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration
Oct
31
BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years